11/12/2025
🚨 New Study of 2.9 Million U.S. Adults Links mRNA COVID Vaccines to Elevated Risks of Kidney Injury and Dialysis
A peer-reviewed analysis published November 10, 2025, in the International Journal of Medical Sciences reports significantly higher rates of acute kidney injury (AKI) and end-stage renal disease requiring dialysis among recipients of mRNA COVID-19 vaccines compared with unvaccinated controls.
The retrospective cohort study, conducted by researchers at The Focal Points and affiliated institutions, matched 1,450,351 vaccinated individuals with 1,450,351 unvaccinated counterparts using U.S. electronic health records from January 2021 through December 2023.
Propensity-score matching balanced age, s*x, comorbidities, and socioeconomic factors.
📊 Key Findings:
• Acute Kidney Injury: 20% higher risk in the vaccinated group (15,809 cases vs. 11,081 in unvaccinated). Risk continued to rise at 6 and 12 months after vaccination.
• Dialysis Initiation: 84% higher risk (1,513 new cases in vaccinated vs. 697 in unvaccinated). Both Pfizer and Moderna showed increased risk with no signs of leveling off.
• All-Cause Mortality: Overall mortality appeared lower in vaccinated (12% reduction), but Pfizer recipients had a 20% higher death risk after excluding early post-vaccination deaths.
The authors note that excluding deaths within 90 days of vaccination may create immortal time bias, potentially hiding early heart and clot-related events that affect the kidneys.
📊 Corroborating Evidence:
• 211,000 excess AKI-related deaths recorded on U.S. death certificates from 2021–2024
• Similar AKI increases seen in a separate Florida study of 1.47 million adults
• VAERS reports showed AKI occurring 2.4 times more often than expected after mRNA vaccination
Lead investigator Dr. James Carter stated: “The trajectory of kidney injury and dialysis risk shows no stabilization, raising concerns about long-term microvascular sequelae of repeated mRNA exposure.”
The study calls for prospective renal monitoring protocols and re-evaluation of booster policies in patients with pre-existing kidney disease.
🔗 Full text: https://www.medsci.org/v22p4483.htm
🔗 Full article: https://www.thefocalpoints.com/p/breaking-29-million-person-study